Clinical Policy: Midostaurin (Rydapt)
Defines medical necessity criteria, initial and continued therapy approval conditions, dosing limits, covered indications (FDA-approved AML and systemic mastocytosis indications) and select off-label uses (myeloid/lymphoid neoplasm with eosinophilia and FGFR1 or FLT3 rearrangements; ISM and SSM), approval durations by line of business, and documentation/prior authorization expectations for midostaurin (Rydapt).
2Q 2025 annual review: for AML added use as maintenance therapy for those who have previously received a FLT3 inhibitor and do not have an allogeneic hematopoietic cell transplantation planned per NCCN; for systemic mastocytosis, revised to include off-label use in ISM and SSM per NCCN.
2Q 2024 annual review: per NCCN for AML, added that Rydapt may also be prescribed with idarubicin for induction therapy and added off-label use for maintenance therapy; for systemic mastocytosis, added that Rydapt must be prescribed as a single agent.
2Q 2022 annual review: modified commercial approval duration to 12 months or duration of request and consolidated approval durations to 6 months initial and 12 months for continuation of therapy; added post-induction use in AML and chronic phase option for myeloid/lymphoid neoplasm.
02.21.21 annual review: added standard oncology generic redirection language and off-label indication for myeloid/lymphoid neoplasm with eosinophilia and FGFR1 or FLT3 rearrangements in blast phase.
2Q 2023 annual review: no significant changes; references reviewed and updated.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.